Join Us for a Special Webinar Featuring the New TK 210 ELISA Assay Kit
Wednesday, November 15, 2017 at 10:00 AM EST
AroCell TK 210 ELISA:
A Novel Proliferation Biomarker to
Study Hematological Malignancies
Thymidine Kinase 1 (TK1) has been long known as a valuable biomarker of cellular proliferation. However, previous methods have been based on enzyme activity measurements that are complex and require specialized equipment. Introducing the AroCell TK 210 ELISA as a new valuable assay for TK1 that brings the simplicity and robustness in a widely available assay kit (sold only in the US by Eagle Biosciences). Based on unique monoclonal antibodies (TK 210 epitope), the AroCell TK 210 ELISA Assay Kit creates an easy to use assay and provides new opportunities for studying cellular proliferation, tumor cell turnover and therapy response in subjects with hematological malignancies.
During this webinar, you will learn the importance of proliferation biomarkers, and their key role in monitoring malignancies, as well as the aiding in making prognoses which could provide early insights into the effects of therapy. Since Thymidine kinase 1 (TK1) is a well-known proliferation biomarker, studying this biomarker has been based on enzyme activity methods and may underestimate serum TK1 levels, particularly in subjects with solid tumors. Improved immunoassays of TK1 based on the TK 210 antigen (AroCell TK 210 ELISA) has shown promising insight of studying these hematological malignancies.
Meet the Speakers:
Staffan Eriksson | Professor in Medical and Physilogical Chemistry at the
Swedish University of Agricultural Sciences
Steffan Eriksson has been active in the research of medical biochemistry and Thymidine Kinase for many decades, and has published over 120 scientific studies related to these topics. He is also founder of AroCell AB and one of the inventors of the TK 210 ELISA Assay test for measuring cell grown and turnover.
Martin Shaw | AroCell Development Manager
Martin Shaw has had a long experience in the development and application of many novel biomarkers. He has participated in industry-wide consortia on the qualification of biomarkers for application in pre-clinical and clinical trials. He has spoken at many congresses including being a guest speaker at the FDA.
We Hope You Can Join Us!
If you would like to receive a white paper on the use of TK1 and TK 210
ELISA in studying hematological malignancies, please click here
